MUNICH, March 6, 2018 /PRNewswire/ --
Blockchain Genomics Pioneer Joins Forces with Nasdaq-Listed
Molecular Diagnostics Company To Accelerate Cancer Detection
Through 'Critical Mass' of Genomics
Data
Shivom, the blockchain-powered global 'Unique ID' genomic
database platform, has today announced a major partnership with
leading molecular diagnostics company Genetic Technologies Limited
(ASX: GTG; NASDAQ: GENE) to accelerate the prediction of cancer for
millions of individuals worldwide.
GTG, whose lead product is BREVAGenplus® - a
clinically validated risk assessment test for non-hereditary breast
cancer - is at the forefront of preventive medicine. However,
collecting data to develop the BREVAGenplus®
tests has to date taken over seven years and the company's
partnership with Shivom will massively reduce such timelines.
"By bringing together the millions of individuals' genomic
profiles that Shivom enables, with GTG's market leading tests, we
will create critical mass that accelerates transformative disease
prevention and personalized healthcare," said Dr. Axel Schumacher, co-founder & CEO of
Shivom.
"This sort of big data analysis and healthcare servicing is only
possible through blockchain. The low-cost management of data that
it enables, allows us to revolutionize how genomics is presented to
the world," added Gourish Singla,
Co-Founder & COO of Shivom.
Shivom have created a secure global genomic ecosystem that aims
to become the largest healthcare data-hub on the planet. Crucially
it puts ownership of genome data back into the hands of
individuals. Via its 'first of a kind' Global Genome ID, Shivom
aims to revolutionize preventative healthcare, as well as how cures
to 7,000 rare genetic diseases are discovered.
"We believe blockchain technology will open up markets to make
it much more efficient to catch many more users and practitioners.
Not only that, by using the Shivom platform to its full potential,
we will also be able to access the benefits of research in
collaboration with other personalized healthcare organisations,"
commented Dr Paul Kasian, Chairman
& Interim CEO of GTG.
"Blockchain's role in this project, especially around the
encryption and management of data, is particularly exciting for us.
At present, we only use genomic data on a one-off basis. However,
now we'll be able to use the data over and over again. This will be
extremely valuable for GTG as we create genomics tests for a wide
range of cancers," added Dr Kasian.
GTG's BREVAGenPlus provides a method of assessing the
risk of non-hereditary breast cancer in women (a cancer that 1 in
every 11 women develops in their lifetime). The volume of unique
and ethnically diverse global genomic data that will be available
via Shivom's platform will hugely accelerate this process for new
tests.
About Shivom
Shivom is powering the next era of genomics through blockchain
technology - protecting identity, personalizing healthcare and
transforming lives. A precision medicine ecosystem will offer an
open web-marketplace for other providers to add not only genomics
information, but also analytics, and associated apps and services
to drive personalized medicine. For further information, please
visit: https://shivom.io/
About Genetic Technologies Limited
Genetic Technologies is a molecular diagnostics company offering
cancer predictive testing and assessment tools to help physicians
proactively manage patient health. The Company's lead product,
BREVAGenplus®, is a clinically validated risk assessment test for
non-hereditary breast cancer. For more information, please visit
http://www.brevagenplus.com and
http://www.phenogensciences.com.
SOURCE Shivom